Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Inactivation of β-Adrenergic Receptors by N-Ethylmaleimide in S49 Lymphoma Cells

Agonist Induction of Functional Receptor Heterogeneity

GEORGES VAUQUELIN and MICHAEL E. MAGUIRE
Molecular Pharmacology November 1980, 18 (3) 362-369;
GEORGES VAUQUELIN
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL E. MAGUIRE
Department of Pharmacology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

β-Adrenergic agonists appear to induce a conformational change in 65% of the β-adrenergic receptors in wild-type S49 lymphoma cell membranes as shown by the increased sensitivity of a subpopulation of receptor to inactivation by the alkylating agent N-ethylmaleimide (NEM). This inactivation is conveniently monitored through the induction with NEM of a biphasic (-)-isoproterenol displacement curve of [125I]IHYP binding to the receptors. In marked contrast, NEM alone or NEM plus a β-adrenergic antagonist has no effect on receptor binding. The final percentage (65%) of total receptor sites inactivated with agonist plus NEM is not dependent on the concentration of NEM used or on the time of exposure. Agonist plus NEM also causes inactivation of about 75% of the receptors in the S49 lymphoma βd clone, which has about 25% of the β-adrenergic receptor density of wild-type cells. However, agonist plus NEM treatment does not affect receptor binding in unc and cyc- S49 cell membranes, in which the receptors are functionally uncoupled from the adenylate cyclase complex. Further, agonists plus NEM also cause inactivation of 45 to 60% of the β-adrenergic receptors in turkey erythrocyte membranes, but have no effect on solubilized receptors from the same cell. These findings with variant S49 lines and turkey erythrocytes suggest that the ability of agonists to produce a conformational change of β-adrenergic receptors may be dependent on the ability of these receptors to interact with the adenylate cyclase complex and specifically to interact with the guanine nucleotide regulatory protein. The fact that only a given fraction of the total receptor population can undergo a conformational change in the investigated membranes and that the properties of the agonist/NEM-sensitive population of receptors but not the insensitive population are similar to those of receptors which activate adenylate cyclase suggests that, for structural or stoichiometric reasons, only part of the receptor population can be coupled to the cyclase complex in the presence of agonists. Thus agonist appears to induce a quantifiable, functional heterogeneity in an apparently molecularly homogeneous receptor population.

ACKNOWLEDGMENTS The skillful technical assistance of Paula L. Jacobs is greatly appreciated. We thank Dr. Henry Bourne for cultures of the βd variant of the S49 cell line.

  • Copyright © 1980 by The American Society for Pharmacology and Experimental Therapeutics

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 18, Issue 3
1 Nov 1980
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inactivation of β-Adrenergic Receptors by N-Ethylmaleimide in S49 Lymphoma Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inactivation of β-Adrenergic Receptors by N-Ethylmaleimide in S49 Lymphoma Cells

GEORGES VAUQUELIN and MICHAEL E. MAGUIRE
Molecular Pharmacology November 1, 1980, 18 (3) 362-369;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inactivation of β-Adrenergic Receptors by N-Ethylmaleimide in S49 Lymphoma Cells

GEORGES VAUQUELIN and MICHAEL E. MAGUIRE
Molecular Pharmacology November 1, 1980, 18 (3) 362-369;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics